These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23506002)

  • 1. New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158).
    Li NG; Tang YP; Duan JA
    Expert Opin Ther Pat; 2013 May; 23(5):669-75. PubMed ID: 23506002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
    Li NG; Tang YP; Duan JA; Shi ZH
    Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of matrix metalloproteinase inhibitors by chemical arrays.
    Kawatani M; Fukushima Y; Kondoh Y; Honda K; Sekine T; Yamaguchi Y; Taniguchi N; Osada H
    Biosci Biotechnol Biochem; 2015; 79(10):1597-602. PubMed ID: 25988721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors.
    Xi L; Li S; Yao X; Wei Y; Li J; Liu H; Wu X
    Arch Pharm (Weinheim); 2014 Nov; 347(11):825-33. PubMed ID: 25363411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.
    Cheng XC; Wang RL; Dong ZK; Li J; Li YY; Li RR
    Bioorg Med Chem; 2012 Oct; 20(19):5738-44. PubMed ID: 22967811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).
    Yuan H; Lu W; Wang L; Shan L; Li H; Huang J; Sun Q; Zhang W
    Eur J Med Chem; 2013 Apr; 62():148-57. PubMed ID: 23353736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis.
    Lim NH; Meinjohanns E; Bou-Gharios G; Gompels LL; Nuti E; Rossello A; Devel L; Dive V; Meldal M; Nagase H
    Arthritis Rheumatol; 2014 Mar; 66(3):589-98. PubMed ID: 24574219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
    Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
    J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.
    Nuti E; Panelli L; Casalini F; Avramova SI; Orlandini E; Santamaria S; Nencetti S; Tuccinardi T; Martinelli A; Cercignani G; D'Amelio N; Maiocchi A; Uggeri F; Rossello A
    J Med Chem; 2009 Oct; 52(20):6347-61. PubMed ID: 19775099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.
    Shi ZH; Li NG; Shi QP; Tang H; Tang YP; Li W; Yin L; Yang JP; Duan JA
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1206-11. PubMed ID: 23375794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
    Ramezani M; Shamsara J
    Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Synthesis of Water-Soluble and Potent MMP-13 Inhibitors with Activity in Human Osteosarcoma Cells.
    Zapico JM; Acosta L; Pastor M; Rangasamy L; Marquez-Cantudo L; Coderch C; Ortin I; Nicolau-Sanus M; Puchades-Carrasco L; Pineda-Lucena A; Majali-Martinez A; Ramos P; de Pascual-Teresa B; Ramos A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.
    Agamennone M; Belov DS; Laghezza A; Ivanov VN; Novoselov AM; Andreev IA; Ratmanova NK; Altieri A; Tortorella P; Kurkin AV
    ChemMedChem; 2016 Sep; 11(17):1892-8. PubMed ID: 27418256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.